tradmap

ELUT ELUTIA INC.

$1.05 +5.92%

Healthcare · Biological Products, (No Diagnostic Substances)

ELUTIA INC. (ELUT) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $45 million. Shares last traded at $1.05, 59.6% below their 52-week high. Over the past year the stock is down 40.0%. ELUT trades at a price-to-earnings ratio of 0.85, below the Biological Products, (No Diagnostic Substances) median of 22.74. Net profit margin is 434.2%, above the peer median of 6.3%. Revenue declined 15.0% year over year.

Market Cap
$45M
Shares Out
43.0M
EPS (TTM)
$-1.51
P/E Ratio
0.85
P/S Ratio
3.67
P/B Ratio
2.00
Dividend / Share
Dividend Yield
52-Week High
$2.60
52-Week Low
$0.50
Volume
2,105
Avg Vol (3m)
2,867.302

Performance

1W
+10.46%
1M
-5.41%
3M
-4.55%
6M
+56.72%
YTD
+63.25%
1Y
-40.00%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
51.48
SMA (50)
$1.07
SMA (200)
$0.98
Price vs SMA50
-1.70%
Price vs SMA200
+7.13%
ATR (14)
$0.06

Financials

Revenue
$12M
Net Income
$53M
Gross Margin
53.7%
Operating Margin
-218.9%
Net Margin
434.2%
Return on Equity
237.0%
Return on Assets
96.7%
Current Ratio
2.05
Debt / Equity
1.16
Revenue Growth (YoY)
-15.0%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.17 2026-05-15
FY 2025 $0.87 2026-03-13
Q3 2025 $-0.66 2025-11-12
Q2 2025 $-0.47 2025-08-14
Q1 2026 $-0.21 2026-05-15
FY 2025 $-1.86 2026-03-13

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

ELUT vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/E vs peers
0.85 / 22.74 med
-96% discount
P/S vs peers
3.67 / 5.21 med
-30% discount
Net margin vs peers
434.2% / 6.3% med
above median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.